Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Nhu Co's ROE % for the quarter that ended in Jun. 2026 was 24.95%. Zhejiang Nhu Co's PB Ratio for the quarter that ended in Jun. 2026 was 2.50.
Zhejiang Nhu Co's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was 9.98%.
Zhejiang Nhu Co ROE % Adjusted to Book Value Related Terms
Zhejiang Nhu Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Zhejiang Nhu Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Nhu Co ROE % Adjusted to Book Value Chart
SZSE:002001 vs ZTS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Nhu Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Zhejiang Nhu Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 9.98% mean?
Zhejiang Nhu Co (SZSE:002001) has a ROE % Adjusted to Book Value of 9.98% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Zhejiang Nhu Co and its competitors.
Is Zhejiang Nhu Co's ROE % Adjusted to Book Value too high?
Zhejiang Nhu Co's current ROE % Adjusted to Book Value is 9.98%. Overall, Zhejiang Nhu Co has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Nhu Co's ROE % Adjusted to Book Value compare to ZTS?
Zhejiang Nhu Co's ROE % Adjusted to Book Value of 9.98% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Zhejiang Nhu Co and its competitors. Zhejiang Nhu Co's current ROE % Adjusted to Book Value is 9.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Nhu Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Nhu Co (SZSE:002001) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.59, compared to a current price of ¥26.40 — trading 7.7% below its estimated fair value. The current ROE % Adjusted to Book Value is 9.98%. Zhejiang Nhu Co's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Zhejiang Nhu Co (SZSE:002001), the current ROE % Adjusted to Book Value is 9.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Nhu Co (SZSE:002001) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Nhu Co stock appears to be undervalued.
The current stock price of ¥26.40 is trading 7.7% below its estimated GF Value™ of ¥28.59.
GuruFocus considers Zhejiang Nhu Co to be Fairly Valued.
Key valuation signals for SZSE:002001:
ROE % Adjusted to Book Value: 9.98%
GF Value™: ¥28.59 vs. price of ¥26.40 (7.7% below fair value)
No single metric tells the full story. See the SZSE:002001 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives, and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer, and Anti-bacterial, with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3, and coenzyme Q10, and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
98GF Score
Get the complete analysis for SZSE:002001
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002001 has been successfully added to your 
